Harvard Bioscience (HBIO) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Nephros (NEPH) over the past year, gaining 84.8% versus a loss of 36.2%. Over five years, NEPH leads with a -57.6% price change compared with -88.1% for HBIO. Harvard Bioscience is the larger company by market cap ($37.0 million vs $35.7 million), about 1.0 times the size.
On valuation, Harvard Bioscience trades at a lower forward P/E (12.6x vs 15.7x for Nephros).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | NEPH |
|---|---|---|
| Share price | $8.13 | $3.29 |
| Market cap | $37.01M | $35.73M |
| 1-day change | -4.35% | +2.81% |
| YTD return | +21.34% | -32.58% |
| 1-year return | +84.77% | -36.24% |
| 5-year return | -88.11% | -57.60% |
| P/E ratio (TTM) | — | 21.93 |
| Forward P/E | 12.60 | 15.67 |
| EPS (TTM) | $-2.31 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.40 | $6.42 |
| 52-week low | $3.80 | $2.66 |
| Distance from 52-week high | -13.51% | -48.75% |
| Analyst consensus | none | none |
| Avg. price target upside | -7.75% | +89.97% |
| Average volume | 17.98K | 27.59K |
| Shares outstanding | 4.55M | 10.86M |
| Employees | 316 | 36 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HBIO has outperformed NEPH by 121.0 percentage points over the past year.
- The two companies sit in different sectors: Harvard Bioscience in Industrials and Nephros in Health Care.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
HBIO vs NEPH FAQ
Which is bigger, Harvard Bioscience or Nephros?
Harvard Bioscience (HBIO) is larger, with a market capitalization of $37.01M compared with $35.73M for Nephros (NEPH).
Which stock has performed better over the past year, HBIO or NEPH?
HBIO returned +84.77% over the past 12 months, compared with -36.24% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Nephros in the same industry?
No. Harvard Bioscience is in the Industrials sector, while Nephros is in Health Care.